Correlation Between Inozyme Pharma and Vir Biotechnology
Can any of the company-specific risk be diversified away by investing in both Inozyme Pharma and Vir Biotechnology at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Inozyme Pharma and Vir Biotechnology into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Inozyme Pharma and Vir Biotechnology, you can compare the effects of market volatilities on Inozyme Pharma and Vir Biotechnology and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Inozyme Pharma with a short position of Vir Biotechnology. Check out your portfolio center. Please also check ongoing floating volatility patterns of Inozyme Pharma and Vir Biotechnology.
Diversification Opportunities for Inozyme Pharma and Vir Biotechnology
-0.35 | Correlation Coefficient |
Very good diversification
The 3 months correlation between Inozyme and Vir is -0.35. Overlapping area represents the amount of risk that can be diversified away by holding Inozyme Pharma and Vir Biotechnology in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Vir Biotechnology and Inozyme Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Inozyme Pharma are associated (or correlated) with Vir Biotechnology. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Vir Biotechnology has no effect on the direction of Inozyme Pharma i.e., Inozyme Pharma and Vir Biotechnology go up and down completely randomly.
Pair Corralation between Inozyme Pharma and Vir Biotechnology
Given the investment horizon of 90 days Inozyme Pharma is expected to under-perform the Vir Biotechnology. But the stock apears to be less risky and, when comparing its historical volatility, Inozyme Pharma is 1.81 times less risky than Vir Biotechnology. The stock trades about -0.53 of its potential returns per unit of risk. The Vir Biotechnology is currently generating about 0.21 of returns per unit of risk over similar time horizon. If you would invest 740.00 in Vir Biotechnology on October 26, 2024 and sell it today you would earn a total of 380.00 from holding Vir Biotechnology or generate 51.35% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Insignificant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Inozyme Pharma vs. Vir Biotechnology
Performance |
| Timeline |
| Inozyme Pharma |
| Vir Biotechnology |
Inozyme Pharma and Vir Biotechnology Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Inozyme Pharma and Vir Biotechnology
The main advantage of trading using opposite Inozyme Pharma and Vir Biotechnology positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Inozyme Pharma position performs unexpectedly, Vir Biotechnology can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Vir Biotechnology will offset losses from the drop in Vir Biotechnology's long position.| Inozyme Pharma vs. Day One Biopharmaceuticals | Inozyme Pharma vs. X4 Pharmaceuticals | Inozyme Pharma vs. Acumen Pharmaceuticals | Inozyme Pharma vs. Mereo BioPharma Group |
| Vir Biotechnology vs. CureVac NV | Vir Biotechnology vs. Krystal Biotech | Vir Biotechnology vs. Propanc Biopharma | Vir Biotechnology vs. Blueprint Medicines Corp |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Other Complementary Tools
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |